SCHEMBL4850508

SCHEMBL4850508

COc1cc(COc2nn(Cc3ccccc3)cc2/C=C/C(=O)O)ccc1OCc1nc(-c2ccco2)oc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.48
PTGER4 P35408 3/20 0.44
PTGER2 P43116 3/20 0.44
SMN1; SMN2 Q16637 6/20 0.43
KDM4E B2RXH2 5/20 0.43
TSHR P16473 4/20 0.43
ALDH1A1 P00352 4/20 0.43
HSD17B10 Q99714 3/20 0.43
HPGD P15428 3/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 3/20 0.40
ALOX15 P16050 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PTGER3 P43115 3/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
GAA P10253 1/20 0.38
PPARA Q07869 1/20 0.38
USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4850519 1.00 PPARG (0.48) PPARGPTGER4PTGER2SMN1; SMN2KDM4E
SCHEMBL4852732 0.93 PPARG (0.49) PPARGPTGER4PTGER2SMN1; SMN2KDM4E
SCHEMBL4852715 0.93 PPARG (0.49) PPARGPTGER4PTGER2SMN1; SMN2KDM4E
SCHEMBL4846347 0.92 PPARG (0.52) PPARGPTGER4PTGER2SMN1; SMN2KDM4E
SCHEMBL4850700 0.92 PPARG (0.50) PPARGPTGER4PTGER2SMN1; SMN2KDM4E
SCHEMBL4846344 0.92 PPARG (0.52) PPARGPTGER4PTGER2SMN1; SMN2KDM4E
SCHEMBL4845621 0.90 PPARG (0.48) PPARGPTGER4PTGER2SMN1; SMN2KDM4E
SCHEMBL4845632 0.90 PPARG (0.48) PPARGPTGER4PTGER2SMN1; SMN2KDM4E
SCHEMBL4846867 0.89 PPARG (0.47) PPARGSMN1; SMN2KDM4ETSHRALDH1A1
SCHEMBL4854552 0.89 PPARG (0.51) PPARGSMN1; SMN2KDM4ETSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 PPARG 536/4885PTGER4 2570/4885PTGER2 4130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.